Home > Signaling Pathways>MAPK>MNK>Tomivosertib (eFT-508)
Tomivosertib (eFT-508)

This product is for research use only, not for human use. We do not sell to patients.

Tomivosertib (eFT-508)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$1150In Stock
250mg$1850In Stock
500mg$2775In Stock

Cat #: V2662 CAS #: 1849590-01-7 Purity ≥ 98%

Description: Tomivosertib (also known as eFT508) is a potent, highly selective, reversible, ATP-competitive and orally bioavailable inhibitor of MNK1 and MNK2 (Mitogen-Activated Protein Kinase Interacting Kinase) with IC50 values of 1-2 nM against both isoforms in enzyme assays.

References: Kevin R. Webster, et al. eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2015 126:1554.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)340.38
Molecular FormulaC17H20N6O2
CAS No.1849590-01-7
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 13 mg/mL (38.2 mM)r
Water: <1 mg/mLr
Ethanol: <1 mg/mL
SMILES CodeNC1=NC=NC(NC2=CC(C)=C3N(C4(CCCCC4)NC3=O)C2=O)=C1
SynonymsTomivosertib; eFT-508; eFT 508; eFT508
ProtocolIn VitroTomivosertib (eFT508) reduces eIF4E phosphorylation dose-dependently at serine 209 (IC50=2-16 nM) in tumor cell lines. In a panel of appr 50 hematological cancers, Tomivosertib shows anti-proliferative activity against multiple DLBCL cell lines. Sensitivity to Tomivosertib in TMD8, OCI-Ly3 and HBL1 DLBCL cell lines is associated with dose-dependent decreases in production of pro-inflammatory cytokines including TNFα, IL-6, IL-10 and CXCL10. Further evaluation Tomivosertib mechanism of action demonstrates that decreased TNFα production correlates with a 2-fold decrease in TNFα mRNA half-life.
In VivoTomivosertib (eFT508) shows significant anti-tumor activity in the TMD8 and HBL-1 ABC-DLBCL models, both of which harbor activating MyD88 mutations. Besides, Tomivosertib combines effectively with components of R-CHOP and with novel targeted agents, including PCI-32765 and Venetoclax, in human lymphoma models.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.9379 mL14.6895 mL29.3789 mL58.7579 mL
5mM0.5876 mL2.9379 mL5.8758 mL11.7516 mL
10mM0.2938 mL1.4689 mL2.9379 mL5.8758 mL
20mM0.1469 mL0.7345 mL1.4689 mL2.9379 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.